{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:02:51Z","timestamp":1785816171341,"version":"3.56.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["PVRetro2"],"award-info":[{"award-number":["PVRetro2"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsmedizin Greifswald"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Patients with polycythemia vera (PV) show an elevated incidence of thromboembolic complications and decreased survival when compared to age-matched healthy individuals. Hypercellularity as indicated by elevated hematocrit, pathophysiological changes induced by the <jats:italic>JAK2<\/jats:italic> driver mutation and cardiovascular risk factors contribute to the increased incidence of thromboembolic events. Higher age and a history of thromboembolic events define a high-risk population of PV patients. Depending on the individual risk profile, phlebotomy or pharmacologic cytoreduction is recommended in combination with low-dose acetylsalicylic acid. Stringent cytoreduction is required for effective risk reduction. However, in recent reports, the rate of thromboembolic complications in PV patients under cytoreductive therapy appears still elevated compared to healthy individuals. This study reports on a chart review to assess for cytoreductive therapy of 1440 PV patients in real life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Forty-two eligible hematologists\/oncologists in private practice treating patients with MPN were recruited to participate in a paper\u2013pencil-based survey conducted between January 2019 and March 2020 in Germany. Physicians were asked to report primary documented data obtained from patient charts. Descriptive analyses were conducted to assess for patient characteristics, treatment modalities, risk factors and thromboembolic complications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data were collected from the patient charts of 1440 individuals diagnosed with PV. The patient population was older than those reported in multicenter trials with a median age of 72.2\u00a0years at the time of reporting and 63.5\u00a0years at diagnosis. Age was the main factor accounting for high-risk status with 84.7% of patients being above the age of 60 followed by thromboembolic complications reported in 21.3% of patients. The use of pharmacologic cytoreduction was highly variable between participating centers with an average of 60.7% and a range of 10.1\u2013100%. Hydroxyurea was the most frequently used drug followed by ruxolitinib, while interferons were reported for a minority of patients. For 35.4% of patients a persistent need for phlebotomy in addition to cytoreductive treatment was reported. Although presence of high-risk criteria and insufficient disease control were reported as main triggers to initiate pharmacologic cytoreduction, 28.1% had elevated hematocrit values (&gt;\u200945%) and 38.6% showed persistence of elevated leukocyte count (&gt;\u200910<jats:sup>9\/l<\/jats:sup>) while on cytoreductive treatment. In contrast, physician-reported symptom burden was lower than published in clinical trials and patient-reported outcomes. The rate of patients experiencing thromboembolic complications was 32.2% at any time and 14.3% after diagnosis with most patients receiving acetylsalicylic acid and 10.8% remaining on oral anticoagulants or heparin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Cytoreductive treatment of high-risk PV in real life is highly variable regarding indication for cytoreduction and definition of therapy resistance. This study highlights the need for (i) improved risk stratification for thromboembolic events, (ii) consequent indication of pharmacologic cytoreduction in high-risk PV and (iii) attention to signs of therapy resistance that can trigger an earlier and stringent switch to second line agents.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-021-03855-5","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T16:06:08Z","timestamp":1637597168000},"page":"2693-2705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera"],"prefix":"10.1007","volume":"148","author":[{"given":"Carl C.","family":"Crodel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Jentsch-Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Jacobasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ulsh\u00f6fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regine","family":"Wunschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-1955","authenticated-orcid":false,"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"3855_CR1","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","volume":"119","author":"A Alvarez-Larran","year":"2012","unstructured":"Alvarez-Larran A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernandez-Boluda JC, Ferrer-Marin F, Angona A, Gomez M, Muina B, Guillen H et al (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119:1363\u20131369. https:\/\/doi.org\/10.1182\/blood-2011-10-387787","journal-title":"Blood"},{"key":"3855_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/bjh.13886","volume":"172","author":"A Alvarez-Larran","year":"2016","unstructured":"Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC, Perez-Encinas M, Ferrer-Marin F, Barez A, Martinez-Lopez J, Cuevas B, Mata MI, Garcia-Gutierrez V et al (2016) Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol 172:786\u2013793. https:\/\/doi.org\/10.1111\/bjh.13886","journal-title":"Br J Haematol"},{"key":"3855_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3324\/haematol.2016.152769","volume":"102","author":"A Alvarez-Larran","year":"2017","unstructured":"Alvarez-Larran A, Perez-Encinas M, Ferrer-Marin F, Hernandez-Boluda JC, Ramirez MJ, Martinez-Lopez J, Magro E, Cruz Y, Mata MI, Aragues P et al (2017) Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica 102:103\u2013109. https:\/\/doi.org\/10.3324\/haematol.2016.152769","journal-title":"Haematologica"},{"key":"3855_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"3855_CR5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761\u2013770. https:\/\/doi.org\/10.1200\/JCO.2010.31.8436","journal-title":"J Clin Oncol"},{"key":"3855_CR6","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Gisslinger B, Pieri L et al (2014) In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124:3021\u20133023. https:\/\/doi.org\/10.1182\/blood-2014-07-591610","journal-title":"Blood"},{"key":"3855_CR7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","volume":"126","author":"T Barbui","year":"2015","unstructured":"Barbui T, Masciulli A, Marfisi MR, Tognoni G, Finazzi G, Rambaldi A, Vannucchi A (2015a) White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood 126:560\u2013561. https:\/\/doi.org\/10.1182\/blood-2015-04-638593","journal-title":"Blood"},{"key":"3855_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.64","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Thiele J, Vannucchi AM, Tefferi A (2015b) Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J 5:e337. https:\/\/doi.org\/10.1038\/bcj.2015.64","journal-title":"Blood Cancer J"},{"key":"3855_CR9","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/ajh.24851","volume":"92","author":"T Barbui","year":"2017","unstructured":"Barbui T, Vannucchi AM, Finazzi G, Finazzi MC, Masciulli A, Carobbio A, Ghirardi A, Tognoni G (2017) A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study. Am J Hematol 92:1131\u20131136. https:\/\/doi.org\/10.1002\/ajh.24851","journal-title":"Am J Hematol"},{"key":"3855_CR10","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R et al (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32:1057\u20131069. https:\/\/doi.org\/10.1038\/s41375-018-0077-1","journal-title":"Leukemia"},{"key":"3855_CR11","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","volume":"148","author":"G Barosi","year":"2010","unstructured":"Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Kiladijan JJ, Lengfelder E, Mesa R, Mc Mullin MF et al (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 148:961\u2013963. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.08019.x","journal-title":"Br J Haematol"},{"key":"3855_CR12","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","volume":"121","author":"G Barosi","year":"2013","unstructured":"Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C et al (2013) Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 121:4778\u20134781. https:\/\/doi.org\/10.1182\/blood-2013-01-478891","journal-title":"Blood"},{"key":"3855_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2843","author":"G Benevolo","year":"2021","unstructured":"Benevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH, Cavazzini F, Bonifacio M, Crugnola M, Binotto G et al (2021) Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. Hematol Oncol. https:\/\/doi.org\/10.1002\/hon.2843","journal-title":"Hematol Oncol"},{"key":"3855_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/bjh.12117","volume":"160","author":"G Bonicelli","year":"2013","unstructured":"Bonicelli G, Abdulkarim K, Mounier M, Johansson P, Rossi C, Jooste V, Andreasson B, Maynadie M, Girodon F (2013) Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol 160:251\u2013254. https:\/\/doi.org\/10.1111\/bjh.12117","journal-title":"Br J Haematol"},{"key":"3855_CR15","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41408-017-0035-6","volume":"7","author":"S Cerquozzi","year":"2017","unstructured":"Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A (2017) Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J 7:662. https:\/\/doi.org\/10.1038\/s41408-017-0035-6","journal-title":"Blood Cancer J"},{"key":"3855_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.0954-6820.1962.tb07186.x","volume":"172","author":"E Chievitz","year":"1962","unstructured":"Chievitz E, Thiede T (1962) Complications and causes of death in polycythaemia vera. Acta Med Scand 172:513\u2013523","journal-title":"Acta Med Scand"},{"issue":"7","key":"3855_CR17","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41375-020-0890-1","volume":"34","author":"CC Crodel","year":"2020","unstructured":"Crodel CC, Jentsch-Ullrich K, Koschmieder S, K\u00e4mpfe D, Griesshammer M, D\u00f6hner K, Jost PJ, Wolleschak D, Isfort S, Stegelmann F, Jilg S (2020) Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study. Leukemia 34(7):1949\u20131953","journal-title":"Leukemia"},{"key":"3855_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","author":"V De Stefano","year":"2008","unstructured":"De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Mico C, Tieghi A, Cacciola RR, Santoro C et al (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93:372\u2013380. https:\/\/doi.org\/10.3324\/haematol.12053","journal-title":"Haematologica"},{"key":"3855_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ajh.21593","volume":"85","author":"V De Stefano","year":"2010","unstructured":"De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Mico C, Tieghi A, Cacciola RR, Santoro C et al (2010) Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol 85:97\u2013100. https:\/\/doi.org\/10.1002\/ajh.21593","journal-title":"Am J Hematol"},{"key":"3855_CR20","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/leu.2016.85","volume":"30","author":"V De Stefano","year":"2016","unstructured":"De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larran A, Iurlo A, Randi ML, Elli E, Finazzi MC, Finazzi G, Zetterberg E et al (2016) High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia 30:2032\u20132038. https:\/\/doi.org\/10.1038\/leu.2016.85","journal-title":"Leukemia"},{"key":"3855_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41408-018-0048-9","volume":"8","author":"V De Stefano","year":"2018","unstructured":"De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML et al (2018) Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer J 8:25. https:\/\/doi.org\/10.1038\/s41408-018-0048-9","journal-title":"Blood Cancer J"},{"key":"3855_CR22","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/leu.2008.177","volume":"22","author":"G Finazzi","year":"2008","unstructured":"Finazzi G, Barbui T (2008) Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 22:1494\u20131502. https:\/\/doi.org\/10.1038\/leu.2008.177","journal-title":"Leukemia"},{"key":"3855_CR23","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","volume":"105","author":"G Finazzi","year":"2005","unstructured":"Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H et al (2005) Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105:2664\u20132670. https:\/\/doi.org\/10.1182\/blood-2004-09-3426","journal-title":"Blood"},{"key":"3855_CR24","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","volume":"138","author":"N Gangat","year":"2007","unstructured":"Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A (2007) Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 138:354\u2013358. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06674.x","journal-title":"Br J Haematol"},{"key":"3855_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1182\/blood.V128.22.475.475","volume":"128","author":"H Gisslinger","year":"2016","unstructured":"Gisslinger H, Klade C, Georgiev P, Skotnicki A, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H et al (2016) Final results from PROUD-PV a randomized controlled phase 3 trial comparing ropeginterferon Alfa-2b to hydroxyurea in polycythemia vera patients. Blood 128:475","journal-title":"Blood"},{"key":"3855_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000485","volume":"4","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H et al (2020) Ropeginterferon Alfa-2b: efficacy and safety in different age groups. Hemasphere 4:e485. https:\/\/doi.org\/10.1097\/HS9.0000000000000485","journal-title":"Hemasphere"},{"key":"3855_CR27","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00277-019-03625-x","volume":"98","author":"M Griesshammer","year":"2019","unstructured":"Griesshammer M, Kiladjian JJ, Besses C (2019) Thromboembolic events in polycythemia vera. Ann Hematol 98:1071\u20131082. https:\/\/doi.org\/10.1007\/s00277-019-03625-x","journal-title":"Ann Hematol"},{"key":"3855_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1945032","author":"M Griesshammer","year":"2021","unstructured":"Griesshammer M, Wille K, Sadjadian P, Stegelmann F, Dohner K (2021) A review of hydroxyurea-related cutaneous adverse events. Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2021.1945032","journal-title":"Expert Opin Drug Saf"},{"key":"3855_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.08.009","volume":"18","author":"MR Grunwald","year":"2018","unstructured":"Grunwald MR, Stein BL, Boccia RV, Oh ST, Paranagama D, Parasuraman S, Colucci P, Mesa R (2018) Clinical and disease characteristics from REVEAL at time of enrollment (baseline): prospective observational study of patients with polycythemia vera in the United States. Clin Lymphoma Myeloma Leuk 18:788. https:\/\/doi.org\/10.1016\/j.clml.2018.08.009","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3855_CR30","doi-asserted-by":"publisher","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","volume":"123","author":"Gruppo Italiano Studio Policitemia","year":"1995","unstructured":"Gruppo Italiano Studio Policitemia (1995) Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 123:656\u2013664. https:\/\/doi.org\/10.7326\/0003-4819-123-9-199511010-00003","journal-title":"Ann Intern Med"},{"key":"3855_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1182\/bloodadvances.2020003628","volume":"5","author":"EN Hamulyak","year":"2021","unstructured":"Hamulyak EN, Daams JG, Leebeek FWG, Biemond BJ, Te Boekhorst PAW, Middeldorp S, Lauw MN (2021) A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms. Blood Adv 5:113\u2013121. https:\/\/doi.org\/10.1182\/bloodadvances.2020003628","journal-title":"Blood Adv"},{"key":"3855_CR32","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","volume":"96","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A et al (2017) The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol 96:1653\u20131665. https:\/\/doi.org\/10.1007\/s00277-017-3082-y","journal-title":"Ann Hematol"},{"key":"3855_CR33","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s41375-018-0214-x","volume":"32","author":"FH Heidel","year":"2018","unstructured":"Heidel FH, Al-Ali HK, Hirt C, Kampfe D, Jentsch-Ullrich K, Junghanss C, Nowak R, Schwarzer A, Spohn C, Vucinic V et al (2018) Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. Leukemia 32:2085\u20132087. https:\/\/doi.org\/10.1038\/s41375-018-0214-x","journal-title":"Leukemia"},{"key":"3855_CR34","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00277-020-04350-6","volume":"100","author":"K Huenerbein","year":"2021","unstructured":"Huenerbein K, Sadjadian P, Becker T, Kolatzki V, Deventer E, Engelhardt C, Griesshammer M, Wille K (2021) Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE\/VTE) in myeloproliferative neoplasms. Ann Hematol 100:2015\u20132022. https:\/\/doi.org\/10.1007\/s00277-020-04350-6","journal-title":"Ann Hematol"},{"key":"3855_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/M17-0028","volume":"168","author":"M Hultcrantz","year":"2018","unstructured":"Hultcrantz M, Bjorkholm M, Dickman PW, Landgren O, Derolf AR, Kristinsson SY, Andersson TML (2018) Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med 168:317\u2013325. https:\/\/doi.org\/10.7326\/M17-0028","journal-title":"Ann Intern Med"},{"key":"3855_CR36","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s00432-016-2209-1","volume":"142","author":"K Jentsch-Ullrich","year":"2016","unstructured":"Jentsch-Ullrich K, Eberhardt J, Zeremski V, Koehler M, Wolleschak D, Heidel FH (2016) Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. J Cancer Res Clin Oncol 142:2041\u20132049. https:\/\/doi.org\/10.1007\/s00432-016-2209-1","journal-title":"J Cancer Res Clin Oncol"},{"key":"3855_CR37","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","volume":"108","author":"JJ Kiladjian","year":"2006","unstructured":"Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, Menot ML, Massonnet G, Dutel JL, Ghomari K et al (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108:2037\u20132040. https:\/\/doi.org\/10.1182\/blood-2006-03-009860","journal-title":"Blood"},{"key":"3855_CR38","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112:3065\u20133072. https:\/\/doi.org\/10.1182\/blood-2008-03-143537","journal-title":"Blood"},{"key":"3855_CR39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T, European Collaboration on Low-Dose Aspirin in Polycythemia Vera (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114\u2013124. https:\/\/doi.org\/10.1056\/NEJMoa035572","journal-title":"N Engl J Med"},{"key":"3855_CR40","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41375-020-0909-7","volume":"35","author":"AR Landtblom","year":"2020","unstructured":"Landtblom AR, Andersson TML, Dickman PW, Smedby KE, Eloranta S, Batyrbekova N, Samuelsson J, Bjorkholm M, Hultcrantz M (2020) Risk of infections in patients with myeloproliferative neoplasms a population-based cohort study of 8363 patients. Leukemia 35:476","journal-title":"Leukemia"},{"key":"3855_CR41","unstructured":"Lengfelder E, Baerlocher GM, Gisslinger HMG, Petrides PE (2014) Polycythaemia Vera (PV). Onkopedia\u2014Leitlinie der Deutschen Gesellschaft f\u00fcr H\u00e4matologie und Onkologie (DGHO). https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/polycythaemia-vera-pv\/@@guideline\/html\/index.html"},{"key":"3855_CR42","unstructured":"Lengfelder E, Baerlocher GM, D\u00f6hner K, Gisslinger H, Grie\u00dfhammer M, Petrides PE (2018) Polycythaemia vera (PV). Onkopedia\u2014Leitlinien der DGHO. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/polycythaemia-vera-pv\/@@guideline\/html\/index.html"},{"key":"3855_CR43","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.thromres.2015.02.023","volume":"135","author":"Y Lim","year":"2015","unstructured":"Lim Y, Lee JO, Kim SH, Kim JW, Kim YJ, Lee KW, Lee JS, Bang SM (2015) Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Thromb Res 135:846\u2013851. https:\/\/doi.org\/10.1016\/j.thromres.2015.02.023","journal-title":"Thromb Res"},{"key":"3855_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R et al (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368:22\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1208500","journal-title":"N Engl J Med"},{"key":"3855_CR45","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bjh.15648","volume":"184","author":"MF McMullin","year":"2019","unstructured":"McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, Garg M, Godfrey A et al (2019) A guideline for the diagnosis and management of polycythaemia vera. A British society for haematology guideline. Br J Haematol 184:176\u2013191. https:\/\/doi.org\/10.1111\/bjh.15648","journal-title":"Br J Haematol"},{"key":"3855_CR46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG et al (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark survey. BMC Cancer 16:167. https:\/\/doi.org\/10.1186\/s12885-016-2208-2","journal-title":"BMC Cancer"},{"key":"3855_CR47","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/cncr.30325","volume":"123","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG et al (2017) Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: findings from the MPN Landmark survey. Cancer 123:449\u2013458. https:\/\/doi.org\/10.1002\/cncr.30325","journal-title":"Cancer"},{"key":"3855_CR48","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/cncr.32664","volume":"126","author":"F Palandri","year":"2020","unstructured":"Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH et al (2020) Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer 126:1243\u20131252. https:\/\/doi.org\/10.1002\/cncr.32664","journal-title":"Cancer"},{"key":"3855_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-016-0031-8","volume":"5","author":"S Parasuraman","year":"2015","unstructured":"Parasuraman S, DiBonaventura M, Reith K, Naim A, Concialdi K, Sarlis NJ (2015) Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. Exp Hematol Oncol 5:3. https:\/\/doi.org\/10.1186\/s40164-016-0031-8","journal-title":"Exp Hematol Oncol"},{"key":"3855_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080854","author":"F Perner","year":"2019","unstructured":"Perner F, Perner C, Ernst T, Heidel FH (2019) Roles of JAK2 in aging, inflammation hematopoiesis and malignant transformation. Cells. https:\/\/doi.org\/10.3390\/cells8080854","journal-title":"Cells"},{"key":"3855_CR51","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00277-015-2397-9","volume":"94","author":"N Polverelli","year":"2015","unstructured":"Polverelli N, Catani L, Vianelli N, Baccarani M, Cavo M, Palandri F (2015) Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly\/constitutional symptoms. Ann Hematol 94:1585\u20131587. https:\/\/doi.org\/10.1007\/s00277-015-2397-9","journal-title":"Ann Hematol"},{"key":"3855_CR52","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378:615\u2013624. https:\/\/doi.org\/10.1056\/NEJMoa1711948","journal-title":"N Engl J Med"},{"key":"3855_CR53","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41375-020-0945-3","volume":"35","author":"F Stegelmann","year":"2021","unstructured":"Stegelmann F, Wille K, Busen H, Fuchs C, Schauer S, Sadjadian P, Becker T, Kolatzki V, Dohner H, Stadler R et al (2021) Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN)\u2014on behalf of the German Study Group-MPN. Leukemia 35:628\u2013631. https:\/\/doi.org\/10.1038\/s41375-020-0945-3","journal-title":"Leukemia"},{"key":"3855_CR54","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/ajh.23417","volume":"88","author":"A Tefferi","year":"2013","unstructured":"Tefferi A (2013) Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 88:507\u2013516. https:\/\/doi.org\/10.1002\/ajh.23417","journal-title":"Am J Hematol"},{"key":"3855_CR55","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27:1874\u20131881. https:\/\/doi.org\/10.1038\/leu.2013.163","journal-title":"Leukemia"},{"issue":"Suppl 5","key":"3855_CR56","doi-asserted-by":"publisher","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","volume":"26","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kroger N, Thiele J, Buske C, Committee EG (2015a) Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v85-99. https:\/\/doi.org\/10.1093\/annonc\/mdv203","journal-title":"Ann Oncol"},{"key":"3855_CR57","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R et al (2015b) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372:426\u2013435. https:\/\/doi.org\/10.1056\/NEJMoa1409002","journal-title":"N Engl J Med"},{"key":"3855_CR58","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1182\/blood-2019-126410","volume":"134","author":"S Verstovsek","year":"2019","unstructured":"Verstovsek S, De Stefano V, Heidel FH, Zuurman M, Zaiac M, Bigan E, Ruhl M, Meier C, Beffy M, Kiladjian JJ (2019) US optum database study in polycythemia vera patients: thromboembolic events (TEs) with hydroxyurea (HU) Vs ruxolitinib switch therapy and machine-learning model to predict incidence of TES and HU failure. Blood 134:1659","journal-title":"Blood"},{"key":"3855_CR59","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00277-018-3483-6","volume":"98","author":"K Wille","year":"2019","unstructured":"Wille K, Sadjadian P, Becker T, Kolatzki V, Horstmann A, Fuchs C, Griesshammer M (2019) High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. Ann Hematol 98:93\u2013100. https:\/\/doi.org\/10.1007\/s00277-018-3483-6","journal-title":"Ann Hematol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03855-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03855-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03855-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T08:15:14Z","timestamp":1663056914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03855-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3855"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03855-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"28 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study conception and data collection were supported by a grant (PVRetro2) from Novartis Inc. Regine Wunschel is employed by Novartis Inc. Florian Heidel has served as a consultant, speaker and advisory board member for Novartis, Celgene\/BMS, CTI, AOP and Janssen and has received research funding from Novartis, Celgene\/BMS and CTI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No identifiable personal information was collected during the chart review, and the results of the chart review were reported as aggregated datasets of each center. Questionnaires and study materials were reviewed and approved by the institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}